Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug 22;25:446–461.

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 Molecular Vision.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited, used for non-commercial purposes, and is not altered or transformed.

PMC Copyright notice

Tecfidera™ maintenance therapy mitigates optic neuritis in patients with RRMS. A: Schematic of time-to-event intervals analyzed in the retrospective chart study. Interval A corresponds to the time before a diagnosis of multiple sclerosis (MS), Interval B corresponds to time following a diagnosis of MS and the beginning of any treatment, and Interval C corresponds to the time during which patients were maintained on Tecfidera™. All subsequent graphs in this figure (B–F) are cumulative time-to-event curves derived with the Kaplan–Meier nonparametric estimation. Percent on the y-axis indicates the estimated probability of a new episode of optic neuritis not to occur before a given time represented in years on the x-axis. As the overall percentages decrease, the likelihood of shorter times to a recurrence of optic neuritis increases. Consequently, the curves closer to the horizontal axis correspond to patients being sicker. The differences between the Kaplan–Meier curves were assessed with a nonparametric log-rank test. p values less than or equal to 0.05 are considered statistically significant and are marked with asterisks. B: Time-to-event curve comparing Interval A between the control patients (Ctrl) and the patients maintained on Tecfidera™ (Tec). C:Comparison within the Tecfidera™-treated cohort of the time to a recurrence of optic neuritis before an MS diagnosis (Interval A, dark green trace), after MS diagnosis (Interval B, red trace), and during maintenance on Tecfidera™ (Interval C, blue trace). P values are shown for comparisons of Interval A versus B, Interval B versus C, and Interval A versus C. D: Comparison within the control cohort of the time to a recurrence of optic neuritis before (Interval A, lime green trace) and after (Interval B, red trace) a definitive diagnosis of MS and the initiation of treatment. This graph also compares the time to a recurrence of optic neuritis for the Tecfidera™-treated cohort during maintenance therapy on Tecfidera™ (Interval C; blue trace) to each interval of the control cohort (Interval A; lime green trace and Interval B; red trace). E, F: Analysis of Interval B versus C for the Tecfidera™ patient cohort divided into women (E) and men (F). For all graphs, asterisks denote statistical significance for p $\leq$ 0.05.